0001831492-20-000001.txt : 20201112
0001831492-20-000001.hdr.sgml : 20201112
20201110192930
ACCESSION NUMBER: 0001831492-20-000001
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20201112
DATE AS OF CHANGE: 20201110
EFFECTIVENESS DATE: 20201112
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Biocure Technology Inc.
CENTRAL INDEX KEY: 0001831492
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-380257
FILM NUMBER: 201302600
BUSINESS ADDRESS:
STREET 1: 300 - 1055 WEST HASTINGS STREET
CITY: VANCOUVER
STATE: A1
ZIP: V6E 2E9
BUSINESS PHONE: 604-609-7149
MAIL ADDRESS:
STREET 1: 300 - 1055 WEST HASTINGS STREET
CITY: VANCOUVER
STATE: A1
ZIP: V6E 2E9
D
1
primary_doc.xml
X0708
D
LIVE
0001831492
Biocure Technology Inc.
300 - 1055 WEST HASTINGS STREET
VANCOUVER
A1
BRITISH COLUMBIA, CANADA
V6E 2E9
604-609-7149
BRITISH COLUMBIA, CANADA
Gravis Energy Corp.
Sukari Ventures Corp.
None
Corporation
true
Sang Mok
Lee
300 - 1055 West Hastings Street
Vancouver
A1
BRITISH COLUMBIA, CANADA
V6E 2E9
Executive Officer
Director
Konstantin
Konstantin
Lichtenwald
300 - 1055 West Hastings Street
Vancouver
A1
BRITISH COLUMBIA, CANADA
V6E 2E9
Executive Officer
Director
Sang Goo (Collin)
Kim
300 - 1055 West Hastings Street
Vancouver
A1
BRITISH COLUMBIA, CANADA
V6E 2E9
Director
Hans
Frykman
300 - 1055 West Hastings Street
Vancouver
A1
BRITISH COLUMBIA, CANADA
V6E 2E9
Director
Danny
Joh
300 - 1055 West Hastings Street
Vancouver
A1
BRITISH COLUMBIA, CANADA
V6E 2E9
Director
Pharmaceuticals
No Revenues
- 06b
false
2020-10-14
true
true
true
true
true
Units, each comprised of one common share and one common share purchase warrant, with each warrant having a CAD$0.21 exercise price and a 2-year term.
false
0
26639
10656
15983
US dollars have been converted from Canadian dollars using the 0.7611 Bank of Canada daily exchange rate on 10-14-20. Total Remaining to be Sold represents the aggregate exercise price of warrants sold in the offering in the United States.
false
1
0
0
0
true
Proceeds of the offering may be used for general working capital purposes and may thus be used for payments to officers and directors in the ordinary course but have not been specifically earmarked for such payments.
false
Biocure Technology Inc.
/s/ Konstantin Lichtenwald
Konstantin Lichtenwald
Chief Financial Officer
2020-11-10